Dynamics of the structure of non-insulin antihyperglycemic drug use in the treatment of type 2 diabetes mellitus (data from the Moscow segment Federal Diabetes Registry)

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background: Type 2 diabetes mellitus (DM2) remains one of the leading causes of cardiovascular complications, which emphasizes the need for the use of antihyperglycemic drugs that can not only control glucose levels, but also reduce the risk of cardiovascular diseases (CVD) and chronic kidney disease (CKD).

Objective: Assessment of the dynamics of the use of non-insulin antihyperglycemic drugs and dapagliflozin based on data from the Moscow segment of the Federal Diabetes Registry for the period from 2016 to 2025.

Materials and methods: The study was a retrospective analysis of anonymized data. The data source for assessing the frequency of use of various antihyperglycemic drugs included samples of patients from the Moscow segment of the FDR who received therapy with various antihyperglycemic drugs in 2016, 2020, and 2025. To assess the main characteristics of patients with DM2 receiving dapagliflozin therapy, a sample of patients from the Moscow segment of the FDR was formed as of 03/08/2025.

Results: During the follow-up period from 2016 to 2025, the number of patients with DM2, according to the Moscow segment of the FDR, increased by 15.4% (from 303.1 to 349.7 thousand people). The proportion of patients with DM2 using DPP-4 inhibitors has increased by 7.3 times over 10 years (from 3.4 to 24.7%), the proportion of SGLT-2 inhibitors by 24.4 times (from 0.8% to 19.5%), and the proportion of GLP-1 arginine by 39 times (from 0.1 to 3.9%)

Conclusion:

  1. The frequency of using drugs with proven cardio-nephroprotective properties in the treatment of patients with type 2 diabetes mellitus has been steadily increasing over the past 10 years.
  2. Over the past 10 years, SGLT-2 inhibitors remain the leading class of antihyperglycemic drugs with proven cardio-nephroprotective properties.
  3. Dapagliflozin is the most frequently used drug from the SGLT-2 inhibitor class when used in patients with type 2 diabetes.

Full Text

Restricted Access

About the authors

Nikolay A. Demidov

Shcherbinskaya Outpatient Clinic

Author for correspondence.
Email: Nicolay13@mail.ru
ORCID iD: 0000-0001-8289-0032
SPIN-code: 7715-4508

Cand. Sci. (Med.), Endocrinologist

Russian Federation, Moscow

References

  1. Дедов И.И., Шестакова М.В., Викулова О.К. и др. Сахарный диабет в Российской Федерации: динамика эпидемиологических показателей по данным Федерального регистра сахарного диабета за период 2010–2022 гг. Сахарный диабет. 2023;26(2):104–123. [Dedov I.I., Shestakova M.V., Vikulova O.K., Zheleznyakova A.V., Isakov M.A., Sazonova D.V., Mokrysheva N.G. Diabetes mellitus in the Russian Federation: dynamics of epidemiological indicators according to the Federal Register of Diabetes Mellitus for the period 2010–2022. Diabetes mellitus. 2023;26(2):104–123. (In Russ.)]. DOI: https://doi.org/10.14341/DM13035.
  2. Wiviott S.D., Raz I., Bonaca M.P. et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–357. doi: 10.1056/NEJMoa1812389.
  3. McMurray J.J.V., Solomon S.D., Inzucchi S.E. et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008. doi: 10.1056/NEJMoa1911303.
  4. Mosenzon O., Wiviott S.D., Cahn A. et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. Lancet Diabetes Endocrinol. 2019;7(8):606–617. doi: 10.1016/S2213-8587(19)30180-9.
  5. Persson F., Nyström T., Jørgensen M.E. et al. Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study. Diabetes Obes Metab. 2018;20(2):344–351. doi: 10.1111/dom.13077.
  6. Zinman B., Wanner C., Lachin J.M. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128. doi: 10.1056/NEJMoa1504720.
  7. Neal B., Perkovic V., Mahaffey K.W. et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–657. doi: 10.1056/NEJMc1712572.
  8. Анциферов М.Б., Демидов Н.А., Балберова М.А. и др. Влияние ингибиторов натрий-глюкозного котранспортера II типа дапаглифлозина на показатели общей смертности больных сахарным диабетом 2 типа (исследование CARDIA-MOS, Москва). Сахарный диабет. 2022;25(5):439–448. [Antsiferov M.B., Demidov N.A., Balberova M.A., Lobanova O.V., Mudrikova I.G., Gusenbekova D.G. Influence of type 2 sodium-glucose co-transporter inhibitors (dapagliflozin) on the indicators of total mortality in patients with type 2 diabetes (CARDIA-MOS study, Moscow). Diabetes mellitus. 2022;25(5):439-448. (In Russ.)]. DOI: https://doi.org/10.14341/DM12929.
  9. Анциферов М.Б., Демидов Н.А. Эффективность дапаглифлозина в отношении улучшения клинических исходов у пациентов с сахарным диабетом 2 типа (продолжение исследования CARDIA-MOS, Москва). Сахарный диабет. 2025;28(1): 80–90. [Antsiferov M.B., Demidov N.A. Dapagliflozin effectiveness in improvement of clinical outcomes in diabetic patients (extention of CARDIA-MOS study, Moscow). Diabetes mellitus. 2025;28(1):80–90. (In Russ.)]. DOI: https://doi.org/10.14341/DM13262.
  10. Анциферов М.Б., Демидов Н.А., Табакаев Н.А. Влияние дапаглифлозина на ожидаемую продолжительность жизни пациентов с сахарным диабетом 2 типа в рутинной клинической практике. Сахарный диабет. 2023;26(4):328–333. [Antsiferov M.B., Demidov N.A., Tabakaev N.A. Impact of dapagliflozin on life expectancy in type 2 diabetes mellitus patients in routine practice. Diabetes mellitus. 2023;26(4):328–333. (In Russ.)]. DOI: https://doi.org/10.14341/DM13010.
  11. Анциферов М.Б., Демидов Н.А., Влияние дапаглифлозина на сердечно-сосудистые исходы при сахарном диабете 2 типа в реальной клинической практике: метаанализ наблюдательных исследований. Consilium Medicum. 2023;25(4):236–240. [Antsiferov M.B, Demidov N.A. Cardiovascular outcomes of dapagliflozin in type 2 diabetes mellitus in real clinical practice: a meta-analysis of observational studies. Consilium Medicum. 2023;25(4):236–240. (In Russ)]. doi: 10.26442/20751753.2023.4.202241.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Figure 1. Structure of use of various classes of non-insulin hypoglycemic drugs in the treatment of type 2 diabetes for the period from 2016 to 2025

Download (69KB)
Indexing metadata
3. Figure 2. Dynamics of the share of use of various drugs of the SGLT-2 class in the treatment of type 2 diabetes according to the Moscow segment of the Federal Diabetes Registry

Download (123KB)
Indexing metadata

Copyright (c) 2025 Bionika Media